Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IDH mutations in older patients with diffuse astrocytic gliomas.

Annals of diagnostic pathology - 1 Dec 2020

Andrews Cyril, Prayson Richard A

Abstract excerpt

In 2016, the World Health Organization recommended that isocitrate dehydrogenase (IDH) mutation status be included in the classification of diffuse astrocytic gliomas. IDH mutations are part of the current definition of oligodendrogliomas and are predictive of a better outcome in diffuse astrocytic gliomas. A few studies, examining the role of routine IDH testing in older patients, came to differing conclusions...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Factors
Share to Aged
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Mutation

Source

Identifiers

PMID: 33137656
DOI: 10.1016/j.anndiagpath.2020.151653

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IDH mutations in older patients with diffuse astrocytic gliomas.PMID 33137656Read ↗

Diffuse gliomas in patients aged 55 years or over: A suggestion for IDH mutation testing.Semantic proximity Read ↗

IDH1-Mutation in Diffuse Gliomas in Persons Age 55 Years and Over.Semantic proximity Read ↗

Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications.Semantic proximity Read ↗

Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations.Semantic proximity Read ↗

Estimation of the occurrence rates of IDH1 and IDH2 mutations in gliomas and the reconsideration of IDH-wildtype anaplastic astrocytomas: an institutional experience.Semantic proximity Read ↗

IDH1 Mutation and World Health Organization 2016 Diagnostic Criteria for Adult Diffuse GliomasSemantic proximity Read ↗

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.Semantic proximity Read ↗

IDH-mutant diffuse gliomas: tips and tricks in the era of genomic tumor classification.Semantic proximity Read ↗

Isocitrate Dehydrogenase IDH1 and IDH2 Mutations in Human Cancer: Prognostic Implications for Gliomas.Semantic proximity Read ↗

Beyond IDH-Mutation: Emerging Molecular Diagnostic and Prognostic Features in Adult Diffuse GliomasSemantic proximity Read ↗

IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee.Semantic proximity Read ↗

Determining IDH-Mutational Status in Gliomas Using IDH1-R132H Antibody and Polymerase Chain ReactionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.